Lantern Pharma Inc. Other General and Administrative Expense
Lantern Pharma Inc. (LTRN) reported Other General and Administrative Expense of $42.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherGeneralAndAdministrativeExpense · last filed 2023-05-09
- Lantern Pharma Inc. other general and administrative expense for the quarter ending 2023-03-31 was $42.00K, a 7.69% increase year-over-year.
- Lantern Pharma Inc. other general and administrative expense for the quarter ending 2022-12-31 was $36.00K, a 5.26% decline year-over-year.
- Lantern Pharma Inc. other general and administrative expense for the quarter ending 2022-09-30 was $30.00K, a 21.05% decline year-over-year.
- Lantern Pharma Inc. other general and administrative expense for the quarter ending 2022-06-30 was $39.00K, a 44.44% increase year-over-year.
- Lantern Pharma Inc. other general and administrative expense for fiscal 2022 was $144.00K, a 37.14% increase from fiscal 2021.
- Lantern Pharma Inc. other general and administrative expense for fiscal 2021 was $105.00K, a 288.89% increase from fiscal 2020.
- Lantern Pharma Inc. other general and administrative expense for fiscal 2020 was $27.00K.
| Period end | Other General and Administrative Expense 3 month | Other General and Administrative Expense 6 month | Other General and Administrative Expense 9 month | Other General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2023-03-31 | $42.00K 10-Q · filed 2023-05-09 | $78.00K derived: sum of 2 quarters · filed 2023-05-09 | $108.00K derived: sum of 3 quarters · filed 2023-05-09 | $147.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | $36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $66.00K derived: sum of 2 quarters · filed 2023-03-20 | $105.00K derived: sum of 3 quarters · filed 2023-03-20 | $144.00K 10-K · filed 2023-03-20 |
| 2022-09-30 | $30.00K 10-Q · filed 2022-11-07 | $69.00K derived: sum of 2 quarters · filed 2022-11-07 | $108.00K 10-Q · filed 2022-11-07 | $146.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-06-30 | $39.00K 10-Q · filed 2022-08-08 | $78.00K 10-Q · filed 2022-08-08 | $116.00K derived: sum of 3 quarters · filed 2023-05-09 | $154.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-03-31 | $39.00K 10-Q · filed 2023-05-09 | $77.00K derived: sum of 2 quarters · filed 2023-05-09 | $115.00K derived: sum of 3 quarters · filed 2023-05-09 | $142.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $76.00K derived: sum of 2 quarters · filed 2023-03-20 | $103.00K derived: sum of 3 quarters · filed 2023-03-20 | $105.00K 10-K · filed 2023-03-20 |
| 2021-09-30 | $38.00K 10-Q · filed 2022-11-07 | $65.00K derived: sum of 2 quarters · filed 2022-11-07 | $67.00K 10-Q · filed 2022-11-07 | $69.00K derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $27.00K 10-Q · filed 2022-08-08 | $29.00K 10-Q · filed 2022-08-08 | $31.00K derived: sum of 3 quarters · filed 2022-08-08 | $32.00K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $2.00K 10-Q · filed 2022-05-03 | $4.00K derived: sum of 2 quarters · filed 2022-05-03 | $5.00K derived: sum of 3 quarters · filed 2022-05-03 | $17.00K derived: sum of 4 quarters · filed 2022-05-03 |
| 2020-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $3.00K derived: sum of 2 quarters · filed 2022-03-10 | $15.00K derived: sum of 3 quarters · filed 2022-03-10 | $27.00K 10-K · filed 2022-03-10 |
| 2020-09-30 | $1.00K 10-Q · filed 2021-11-01 | $13.00K derived: sum of 2 quarters · filed 2021-11-01 | $25.00K 10-Q · filed 2021-11-01 | |
| 2020-06-30 | $12.00K 10-Q · filed 2021-07-29 | $24.00K 10-Q · filed 2021-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |